Ad hoc announcement pursuant to Art. 53 LR

Santhera and ReveraGen Announce FDA Acceptance of New Drug
Application for Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 – Santhera Pharmaceuticals (SIX: SANN)
and ReveraGen BioPharma, Inc announce that the U.S. Food and Drug Administration (FDA) has
accepted the new drug application (NDA) for vamorolone for the treatment of Duchenne muscular
dystrophy (DMD) for filing. The FDA has set October 26, 2023, as the Prescription Drug User Fee Act(PDUFA) target action date.
The PDUFA date is the target date for the FDA to complete its review of the NDA. Furthermore, the FDA
stated that it does not currently plan to hold an advisory committee meeting to discuss the application.
Subject to approval, Santhera plans to launch vamorolone in the U.S. in Q4-2023.
“We are delighted that the FDA has accepted Santhera’s vamorolone NDA for filing. We believe thisproduct addresses a clear unmet medical need and for Santhera, this represents the achievement of animportant milestone with key significance for our future success,” said Dario Eklund, CEO of Santhera.
“We look forward to working closely with U.S. regulators to advance vamorolone towards approval.”“This is an exciting time for the Duchenne community as the data generated across the clinical trial
program indicate that vamorolone has the potential to address relevant aspects in patient care that could
also enhance treatment outcomes,” said Eric Hoffman, PhD, President and CEO of ReveraGen
BioPharma. “If approved, vamorolone will emerge as an additional treatment option in current standardsof care in DMD, with the potential to address unmet medical needs and treat a majority of Duchenne
patients starting at an early age.”
The NDA submission for vamorolone was supported by clinical data from the positive pivotal Phase 2b
VISION-DMD study which met the primary endpoint with statistical significance over placebo [1]. The
data package also included data from four open-label studies (including extension) in which vamorolone
was administered at doses between 2 and 6 mg/kg/day for a total treatment period of up to 30 months[2].
In Europe, a marketing authorization application (MAA), seeking approval for vamorolone in theEuropean Union, has been validated and is under review by the European Medicines Agency (EMA).
Vamorolone has been granted Orphan Drug status in the U.S. and in Europe for DMD, and has received
Fast Track and Rare Pediatric Disease designations by the U.S. FDA and Promising Innovative Medicine(PIM) status from the UK MHRA for DMD.
About Vamorolone
Vamorolone is an investigational drug candidate with a mode of action based on binding to the samereceptor as corticosteroids but modifying its downstream activity and as such is considered a dissociative

Santhera and ReveraGen Announce FDA Acceptance of New Drug Application
for Vamorolone in Duchenne Muscular Dystrophy
January 9, 2023 / Page 2 of 3
anti-inflammatory drug [2-5]. This mechanism has shown the potential to ‘dissociate’ efficacy fromsteroid safety concerns and therefore vamorolone could emerge as an alternative to existingcorticosteroids, the current standard of care in children and adolescent subjects with DMD. In the pivotal
VISION-DMD study, vamorolone met the primary endpoint Time to Stand (TTSTAND) velocity versus
placebo (p=0.002) at 24 weeks of treatment and showed a good safety and tolerability profile [1]. The
most commonly reported adverse events versus placebo from the VISION-DMD study were cushingoidfeatures, vomiting and vitamin D deficiency. Adverse events were generally of mild to moderate severity.
Vamorolone is an investigational medicine and is currently not approved for use by any health authority.
References:[1] Guglieri M et al (2022). JAMA Neurol. Published online August 29, 2022. doi:10.1001/jamaneurol.2022.2480. Link.
[2] Mah JK et al (2022). JAMA Netw Open. 2022;5(1):e2144178. doi:10.1001/jamanetworkopen.2021.44178. Link.
[3] Guglieri, et al (2022) JAMA. doi:10.1001/jama.2022.4315[4] Heier CR at al (2019). Life Science Alliance DOI: 10.26508[5] Liu X, et al (2020). Proc Natl Acad Sci USA 117:24285-24293

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a rare inherited X-chromosome-linked disease, which almost
exclusively affects males. DMD is characterized by inflammation which is present at birth or shortly
thereafter. Inflammation leads to fibrosis of muscle and is clinically manifested by progressive muscle
degeneration and weakness. Major milestones in the disease are the loss of ambulation, the loss of selffeeding, the start of assisted ventilation, and the development of cardiomyopathy. DMD reduces life
expectancy to before the fourth decade due to respiratory and/or cardiac failure. Corticosteroids are thecurrent standard of care for the treatment of DMD.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on thedevelopment and commercialization of innovative medicines for rare neuromuscular and pulmonary
diseases with high unmet medical need. The Company has an exclusive license for all indications
worldwide to vamorolone, a dissociative steroid with novel mode of action, which was investigated in apivotal study in patients with Duchenne muscular dystrophy as an alternative to standard corticosteroids.
Santhera has a new drug application (NDA) under review by the U.S. FDA and a marketing authorization
application (MAA) under review by the European Medicines Agency (EMA) for vamorolone for thetreatment of DMD. The clinical stage pipeline also includes lonodelestat to treat cystic fibrosis (CF) andother neutrophilic pulmonary diseases. Santhera out-licensed rights to its first approved product,
Raxone® (idebenone), outside North America and France for the treatment of Leber's hereditary optic
neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.
Raxone® is a trademark of Santhera Pharmaceuticals.
About ReveraGen BioPharma
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne
muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGen’s leadcompound, vamorolone, has been supported through partnerships with foundations worldwide,including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation toEradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryan’s Quest, Alex’sWish, DuchenneUK, Pietro’s Fight, Michael’s Cause, Duchenne Research Fund, and Defeat Duchenne

Santhera and ReveraGen Announce FDA Acceptance of New Drug Applicationfor Vamorolone in Duchenne Muscular DystrophyJanuary 9, 2023 / Page 3 of 3Canada. ReveraGen has also received generous support from the US Department of Defense CDMRP,National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020).
www.reveragen.com
For further information please contact:
Santhera
Santhera Pharmaceuticals Holding AG, Hohenrainstrasse 24, CH-4133 Pratteln
public-relations@santhera.com or
Eva Kalias, Head Investor Relations & Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com
ReveraGen BioPharma
Eric Hoffman, PhD, President and CEO
Phone: + 1 240-672-0295
eric.hoffman@reveragen.com
Disclaimer / Forward-looking statementsThis communication does not constitute an offer or invitation to subscribe for or purchase any securities
of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking
statements concerning the Company and its business. Such statements involve certain risks,
uncertainties and other factors which could cause the actual results, financial condition, performance orachievements of the Company to be materially different from those expressed or implied by suchstatements. Readers should therefore not place undue reliance on these statements, particularly not in
connection with any contract or investment decision. The Company disclaims any obligation to updatethese forward-looking statements.
###